Dr. Michael D. Zurenko
Claim this profilePrisma Health Cancer Institute - Eastside
Studies Skin Cancer
Studies Prostate Cancer
8 reported clinical trials
16 drugs studied
Area of expertise
1Skin Cancer
p16 negative
EGFR positive
EGFR negative
2Prostate Cancer
Affiliated Hospitals
Clinical Trials Michael D. Zurenko is currently running
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
Radiation Therapy vs Observation
for Meningioma
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting2 awards Phase 312 criteria
More about Michael D. Zurenko
Clinical Trial Related9 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael D. Zurenko has experience with
- Radiation Therapy
- Intensity-Modulated Radiation Therapy
- Atezolizumab
- Cisplatin
- Clinical Observation
- Intensity-Modulated Radiation Therapy (IMRT)
Breakdown of trials Michael D. Zurenko has run
Skin Cancer
Small Cell Lung Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael D. Zurenko specialize in?
Michael D. Zurenko focuses on Skin Cancer and Prostate Cancer. In particular, much of their work with Skin Cancer has involved p16 negative patients, or patients who are EGFR positive.
Is Michael D. Zurenko currently recruiting for clinical trials?
Yes, Michael D. Zurenko is currently recruiting for 3 clinical trials in Greenville South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Michael D. Zurenko has studied deeply?
Yes, Michael D. Zurenko has studied treatments such as Radiation Therapy, Intensity-Modulated Radiation Therapy, Atezolizumab.
What is the best way to schedule an appointment with Michael D. Zurenko?
Apply for one of the trials that Michael D. Zurenko is conducting.
What is the office address of Michael D. Zurenko?
The office of Michael D. Zurenko is located at: Prisma Health Cancer Institute - Eastside, Greenville, South Carolina 29615 United States. This is the address for their practice at the Prisma Health Cancer Institute - Eastside.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.